Changzhou Aron

Changzhou Aron Pharmaceutical is a clinical-stage biopharmaceutical company based in Changzhou, China, focused on the discovery and development of novel small molecule therapeutics. The company primarily targets metabolic, inflammatory, and fibrotic diseases, with a particular emphasis on the Vascular Adhesion Protein-1 (VAP-1) pathway. Its lead candidate, ARN-001, is a potent and selective VAP-1 inhibitor currently in Phase 2 clinical development for non-alcoholic steatohepatitis (NASH) and diabetic nephropathy. By leveraging its internal research capabilities, Changzhou Aron aims to address significant unmet medical needs in the global healthcare market. The company has successfully secured venture backing from prominent investors to advance its innovative pipeline through international clinical trials.